Search Results
Your search for Bradley J. Monk, MD, FACS, FACOG,Bradley J. Monk, MD, FACS, FACOG matches 7 pages
Showing 1 - 7Expert Point of View: Bradley J. Monk, MD, FACS, FACOG
Based on the results of the phase III BEATcc trial, there is no longer doubt that immune checkpoint inhibitors have transformed the treatment landscape in cervical cancer—and there is no place for “skeptics” of this approach, according to Bradley J. Monk, MD, FACS, FACOG, Director and Principal...
Addition of First-Line Pembrolizumab to Chemotherapy, With or Without Bevacizumab, in Advanced Cervical Cancer: Final Overall Survival Results From KEYNOTE-826
In an analysis reported in the Journal of Clinical Oncology, Bradley J. Monk, MD, FACS, FACOG, and colleagues described final overall survival results from the phase III KEYNOTE-826 trial, which evaluated the addition of first-line pembrolizumab to chemotherapy, with or without bevacizumab, in...
Adding Pembrolizumab to Chemotherapy May Improve Survival in Patients With Advanced Cervical Cancer
Adding the PD-1 inhibitor pembrolizumab to chemotherapy, with or without bevacizumab, improved overall survival and progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer, regardless of whether the cancer expressed PD-L1. These findings from the KEYNOTE-826...
How a Recent Study Heats up the Debate Over Intraperitoneal Chemotherapy in Newly Diagnosed Advanced Ovarian Cancer
Based on pharmacokinetic and preclinical data, there appears to be a biologic advantage to the use of intraperitoneal chemotherapy in treating some malignancies confined to the abdomen. Since most ovarian, fallopian tube, and peritoneal cancers present and recur in the peritoneal cavity, this...
PARP Inhibitor Niraparib Yields ‘Unprecedented’ Results in Ovarian Cancer in Phase III Trial
The first phase III trial of an inhibitor of poly (ADP-ribose) polymerase (PARP) yielded unprecedented results in treating ovarian cancer. The trial was presented at the European Society for Medical Oncology (ESMO) in Copenhagen, Denmark, and electronically reported concurrently in The New England ...
Trebananib Improves Progression-Free Survival in Recurrent Ovarian Cancer
Trebananib, an investigational antiangiogenesis inhibitor with a different mechanism of action than bevacizumab (Avastin), significantly improved progression-free survival in recurrent platinum-resistant and partially platinum-sensitive ovarian cancer in the phase III TRINOVA-1 trial. The addition...
Ovarian Cancer: Current Treatment and Patient Management
Tough initial treatment decisions have “long-lasting ramifications and affect the entire treatment paradigm” for women with ovarian cancer, according to Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona Cancer Center, Phoenix. In a true collaborative presentation at the Annual JADPRO...
